Pfizer announced Wednesday that it has begun clinical trials of its COVID-19 pills in children ages 6 to 17.
If approved by regulators, the oral treatment, called Paxlovid, would be used for nonhospitalized, symptomatic pediatric patients who are at risk of developing severe disease.
Pfizer’s clinical trial for adults found the pill was 89% effective against hospitalization and death when taken within three days of developing symptoms, and 88% effective within five days. “There is a significant unmet need for outpatient treatments that can be taken by children and adolescents to help prevent progression to severe illness, including hospitalization or death,” Mikael Dolsten, Pfizer’s chief scientific officer, said in a news release. “ … We are proud to expand studies of our novel COVID-19 treatment to include pediatric participants to further evaluate the safety and efficacy of this treatment in this important population.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Phase 2, 3 trial for Pfizer pill for COVID begins in children ages 6 to 17'There is a significant unmet need for outpatient treatments that can be taken by children and adolescents to help prevent progression to severe illness, including hospitalization or death.'
Read more »
Phase 2, 3 trial for Pfizer pill for COVID begins in children ages 6 to 17'There is a significant unmet need for outpatient treatments that can be taken by children and adolescents to help prevent progression to severe illness, including hospitalization or death.'
Read more »
Phase 2, 3 trial for Pfizer pill for COVID begins in children ages 6 to 17'There is a significant unmet need for outpatient treatments that can be taken by children and adolescents to help prevent progression to severe illness, including hospitalization or death.'
Read more »
Pfizer launches trial to test Covid pill in childrenPfizer's pill, called Paxlovid, is already authorized for use in people ages 12 and up.
Read more »
Pfizer begins next phase of COVID-19 pill trial for childrenThe company announced Wednesday that it has started the second and third test phases for Paxlovid in children ages 6 to 17.
Read more »
Pfizer launches clinical trial testing its COVID-19 pill in children aged 6 and older
Read more »